Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

BACKGROUND: FIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) patients. The consensus molecular subgroups (CMS) are grouping CRC samples according to their gene-signature in four different subtypes. R...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Ann Oncol
Prif Awduron: Stintzing, S, Wirapati, P, Lenz, H -J, Neureiter, D, Fischer von Weikersthal, L, Decker, T, Kiani, A, Kaiser, F, Al-Batran, S, Heintges, T, Lerchenmüller, C, Kahl, C, Seipelt, G, Kullmann, F, Moehler, M, Scheithauer, W, Held, S, Modest, D P, Jung, A, Kirchner, T, Aderka, D, Tejpar, S, Heinemann, V
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2019
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6927316/
https://ncbi.nlm.nih.gov/pubmed/31868905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdz387
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg